Viewing Study NCT06360250

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:48 PM
Ignite Modification Date: 2026-01-24 @ 6:26 AM
Study NCT ID: NCT06360250
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-04-11
First Post: 2024-04-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Sponsor: Changchun BCHT Biotechnology Co.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Clostridium Tetanus View
Keywords:

Keywords

Keyword Brief Keyword Text View
None tolerability View
None Monoclonal antibody to tetanus View
None Safety View
None pharmacokinetics View
None pharmacodynamics View
None immunogenicity View